Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.
Am J Pathol. 2012 Mar;180(3):895-903. Epub 2012 Jan 11.
Related citations
Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia.
García-Cruz E, Piqueras M, Ribal MJ, Huguet J, Serapiao R, Peri L, Izquierdo L, Alcaraz A.
BJU Int. 2012 Jan 18. doi: 10.1111/j.1464-410X.2011.10876.x. [Epub ahead of print]
Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
Gomez-Veiga F, Mariño A, Alvarez L, Rodriguez I, Fernandez C, Pertega S, Candal A.
BJU Int. 2012 Feb;109 Suppl 1:17-21. doi: 10.1111/j.1464-410X.2011.10826.x. Review.
The phantom menace of prostate cancer screening.
Ghani KR, Trinh QD, Menon M.
BJU Int. 2012 Feb;109(3):324-6. doi: 10.1111/j.1464-410X.2011.10881.x. No abstract available.
Obesity, body composition, and prostate cancer.
Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA.
BMC Cancer. 2012 Jan 18;12:23.
Changes in circulating microRNA levels associated with prostate cancer.
Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC.
Br J Cancer. 2012 Feb 14;106(4):768-74. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12.
Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger.
Hoppe BS, Nichols RC, Henderson RH, Morris CG, Williams CR, Costa J, Marcus RB Jr, Mendenhall WM, Li Z, Mendenhall NP.
Cancer. 2012 Jan 17. doi: 10.1002/cncr.27398. [Epub ahead of print]
Explaining racial differences in prostate cancer mortality.
Taksler GB, Keating NL, Cutler DM.
Cancer. 2012 Jan 13. doi: 10.1002/cncr.27379. [Epub ahead of print]
Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.
Gray JK, Paluch AM, Stuart WD, Waltz SE.
Cancer Lett. 2012 Jan 1;314(1):92-101. Epub 2011 Sep 24.
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.
Amato RJ, Stepankiw M.
Clin Med Insights Oncol. 2012;6:67-73. Epub 2012 Jan 5.
Inhibition of migration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt.
Jeong JW, Jin CY, Park C, Han MH, Kim GY, Moon SK, Kim CG, Jeong YK, Kim WJ, Lee JD, Choi YH.
Int J Oncol. 2012 May;40(5):1697-704. doi: 10.3892/ijo.2012.1332. Epub 2012 Jan 13.
Protein-based nanotechnology: antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy.
Jankun J.
Int J Oncol. 2011 Oct;39(4):949-53. doi: 10.3892/ijo.2011.1110. Epub 2011 Jul 1.
High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes.
Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB.
Int J Radiat Oncol Biol Phys. 2012 Jan 13. [Epub ahead of print]
A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M 3rd, Cheung P, Sahgal A.
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e657-62. Epub 2012 Jan 13.
Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM.
J Clin Oncol. 2011 Dec 1;29(34):4510-5. Epub 2011 Oct 24.
Prostatic urethral recurrence of urachal adenocarcinoma.
Ching CB, Chen L, Fergany A.
J Clin Oncol. 2011 Oct 1;29(28):e736-8. Epub 2011 Sep 6. No abstract available.
Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC Map: A prospective large-scale cohort study.
Watanabe Y, Terai A, Araki T, Nagayama M, Okumura A, Amoh Y, Ishimori T, Ishibashi M, Nakashita S, Dodo Y.
J Magn Reson Imaging. 2012 Jun;35(6):1414-21. doi: 10.1002/jmri.23587. Epub 2012 Jan 13.
Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients.
Holmes JA, Carpenter WR, Wu Y, Hendrix LH, Peacock S, Massing M, Schenck AP, Meyer AM, Diao K, Wheeler SB, Godley PA, Stitzenberg KB, Chen RC.
J Urol. 2012 Mar;187(3):883-8. Epub 2012 Jan 15.
Focal therapy will become standard treatment for localized prostate cancer: con.
Nelson JB.
J Urol. 2012 Mar;187(3):791-2. Epub 2012 Jan 15. No abstract available.
Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M, Schalken JA.
J Urol. 2012 Mar;187(3):795-801. Epub 2012 Jan 15. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on